Anti-viral compounds

A compound of Formula (I), or a pharmaceutically acceptable salt thereof, having the structure:

• wherein:
• RN is hydrogen, deuterium or an unsubstituted or a substituted C1-6 alkyl;
• Ring A1 is an unsubstituted or a substituted
• an unsubstituted or a substituted
• an unsubstituted or a substituted
• an unsubstituted or a substituted
• or an unsubstituted or a substituted
• wherein the N is the nitrogen of Ring A1 shown in Formula (I) and the carbon indicated with an asterisk is the carbon to which R4 is connected;
• Ring A2 and Ring A4 are an unsubstituted or a substituted 3- to 10-membered ring system that optionally includes 1 to 3 heteroatoms selected from the group consisting of O, S and N, and wherein Ring A2 and Ring A4 are optionally substituted with one or more moieties independently selected from the group consisting of ═O, ═CH2, deuterium, halogen, hydroxy, an unsubstituted C1-4 alkyl, an unsubstituted C1-4 haloalkyl, an unsubstituted C2-4 alkenyl and an unsubstituted or a substituted C3-6 monocyclic cycloalkyl;
• Ring A3 and Ring A5 are an unsubstituted or a substituted monocyclic C3-6 cycloalkyl;
• R1 is selected from the group consisting of cyano, an unsubstituted or a substituted C2-5 alkynyl, an unsubstituted or a substituted acyl, an unsubstituted or a substituted ketoamide, —CH(OH)—(S(═O)2—OH), —CH(OH)—(S(═O)2—O—), —CH(OH)((P═O)(OR6)2) and —C(═O)CH2—O—((P═O)(OR7)2);
• each R6 and each R7 are independently hydrogen, an unsubstituted C1-6 alkyl, an unsubstituted C2-6 alkenyl, an unsubstituted C1-6 haloalkyl, an unsubstituted or a substituted aryl or an unsubstituted or a substituted aryl(C1-4 alkyl);
• R2 is hydrogen, deuterium, halogen or an unsubstituted C1-4 alkyl;
• and
• R3 is an unsubstituted or a substituted monocyclic nitrogen-containing heteroaryl, an unsubstituted or a substituted bicyclic nitrogen-containing heteroaryl, an unsubstituted or a substituted bicyclic nitrogen-containing heterocyclyl or an unsubstituted or a substituted naphthyl;
• or
• R2 and R3 are taken together along with the carbon to which they are attached to form an unsubstituted or a substituted bicyclic, nitrogen-containing heterocyclyl;
• R4 is hydrogen, deuterium or halogen;
• R5 is
• or R12;
• Z1 is —C(═O)— or —S(═O)2—;
• R8 and R10 are independently selected from the group consisting of an unsubstituted or a substituted C1-6 alkyl, an unsubstituted or a substituted C2-6 alkenyl, an unsubstituted or a substituted C2-6 alkynyl, an unsubstituted or a substituted monocyclic C3-6 cycloalkyl, an unsubstituted or a substituted bicyclic C5-8 cycloalkyl, an unsubstituted or a substituted monocyclic 4- to 6-membered heterocyclyl and an unsubstituted monocyclic C3-6 cycloalkyl(CH2)—,
• wherein when the C1-6 alkyl is substituted, the C1-6 alkyl is substituted 1, 2, 3 or 4 times with a substituent independently selected from the group consisting of halogen, cyano, an unsubstituted or a substituted monocyclic C3-6 cycloalkyl, an unsubstituted C1-4 alkoxy and an unsubstituted C1-4 haloalkoxy, or the C1-6 alkyl is substituted 1 to 13 times with deuterium;
• wherein when the C2-6 alkenyl, the C2-6 alkynyl, the monocyclic C3-6 cycloalkyl, the bicyclic C5-8 cycloalkyl and the monocyclic 4- to 6-membered heterocyclyl are substituted, the C2-6 alkenyl, the C2-6 alkynyl, the monocyclic C3-6 cycloalkyl, the bicyclic C5-8 cycloalkyl and the monocyclic 4- to 6-membered heterocyclyl are substituted 1, 2, 3 or 4 times with a substituent independently selected from the group consisting of halogen, an unsubstituted C1-4 alkyl, an unsubstituted C2-4 alkenyl, an unsubstituted C2-4 alkynyl, an unsubstituted C1-4 haloalkyl, an unsubstituted or a substituted monocyclic C3-6 cycloalkyl and an unsubstituted C1-4 alkoxy;
• and
• R9 is selected from the group consisting of an unsubstituted or a substituted C1-6 alkyl, an unsubstituted or a substituted C1-6 haloalkyl, an unsubstituted or a substituted monocyclic C3-6 cycloalkyl, an unsubstituted or a substituted bicyclic C5-6 cycloalkyl, an unsubstituted or a substituted monocyclic heteroaryl, an unsubstituted or a substituted monocyclic heterocyclyl, an unsubstituted or a substituted alkoxy and —NR17R18, wherein the substituted C1-6 alkyl is substituted 1 or 2 times with an unsubstituted C1-4 alkoxy, wherein the substituted monocyclic C3-6 cycloalkyl is substituted 1, 2, 3 or 4 times with a substituent independently selected from the group consisting of halogen, an unsubstituted C1-4 alkyl, an unsubstituted C2-4 alkenyl, an unsubstituted C1-4 alkoxy, an unsubstituted C1-4 haloalkyl and an unsubstituted monocyclic C3-6 cycloalkyl, and wherein the substituted C1-6 haloalkyl is substituted 1 or 2 times with an unsubstituted C1-4 alkoxy;
• R11 is an unsubstituted or a substituted monocyclic 4- to 6-membered heterocyclyl, —(NH)m-(an unsubstituted or a substituted 5- to 6-membered monocyclic heteroaryl), —O-(an unsubstituted or a substituted C1-6 alkyl), —O-(an unsubstituted or a substituted C3-8 cycloalkyl) or —O—(C1-4 alkyl)-(an unsubstituted or a substituted C3-8 cycloalkyl), wherein m is 0 or 1;
• R12 is an unsubstituted or a substituted C1-8 alkyl, an unsubstituted or a substituted C2-8 alkenyl, an unsubstituted or a substituted C2-8 alkynyl, an unsubstituted or a substituted C3-8 cycloalkyl, an unsubstituted or a substituted aryl, an unsubstituted or a substituted heteroaryl, an unsubstituted or a substituted 3- to 8-membered monocyclic heterocyclyl, an unsubstituted or a substituted aryl(alkyl), an unsubstituted or a substituted heteroaryl(alkyl), an unsubstituted or a substituted heterocyclyl(alkyl), an unsubstituted or a substituted C-carboxy, —OR13, —NR14R15 or —C(═O)—NR16AR16B;
• R13 is an unsubstituted or a substituted C1-8 alkyl, an unsubstituted or a substituted C2-8 alkenyl, an unsubstituted or a substituted C2-8 alkynyl, an unsubstituted or a substituted C3-8 cycloalkyl, an unsubstituted or a substituted aryl, an unsubstituted or a substituted heteroaryl, an unsubstituted or a substituted 3- to 8-membered monocyclic heterocyclyl, an unsubstituted or a substituted aryl(alkyl) or an unsubstituted or a substituted heteroaryl(alkyl);
• R14 and R15 are independently selected from the group consisting of hydrogen, an unsubstituted or a substituted C1-8 alkyl, an unsubstituted or a substituted C2-8 alkenyl, an unsubstituted or a substituted C2-8 alkynyl, an unsubstituted or a substituted C3-8 cycloalkyl, an unsubstituted or a substituted aryl, an unsubstituted or a substituted heteroaryl, an unsubstituted or a substituted 3- to 8-membered monocyclic heterocyclyl, an unsubstituted or a substituted aryl(alkyl) or an unsubstituted or a substituted heteroaryl(alkyl);
• or
• R14 and R15 are taken together with the nitrogen to which R14 and R15 are attached to form an optionally substituted 3- to 8-membered heterocyclyl;
• R16A is hydrogen or an unsubstituted C1-3 alkyl;
• R16B is an unsubstituted or a substituted aryl, an unsubstituted or a substituted heteroaryl or an unsubstituted or a substituted 3- to 8-membered monocyclic heterocyclyl;
• and
• R17 and R18 are independently selected from the group consisting of hydrogen, an unsubstituted or a substituted C1-8 alkyl, an unsubstituted or a substituted C2-8 alkenyl, an unsubstituted or a substituted C2-8 alkynyl, an unsubstituted or a substituted C3-8 cycloalkyl, an unsubstituted or a substituted 3-8 membered heterocyclyl, an unsubstituted or a substituted aryl, an unsubstituted or a substituted heteroaryl, an unsubstituted or a substituted aryl(alkyl) and an unsubstituted or a substituted heteroaryl(alkyl);
• or
• R17 and R18 are taken together along with the nitrogen to which they are connected to form an unsubstituted or a substituted 3-8 membered heterocyclyl;
• and
• provided that when R12 is
• then R2 and R3 cannot be taken together along with the carbon to which they are attached to form an unsubstituted
• and
• provided that Ring A1 cannot be an unsubstituted or a substituted